Dublin
,
Ireland
3 - 6 February 2026
European Association for Hemophilia and Allied Disorders (EAHAD 2026)
Presentation schedule and materials
Wednesday, 04 February 2026
18:30
- 19:30
ET
PO083
POSTER
Concizumab plasma concentration measurements and modelling for personalised dose adjustment in patients with haemophilia A/B with and withoutot inhibitors
Mary Mathias1, Chris Barnes2, Johnny Mahlangu3, Tulika Seth4, Sonata Šaulytė Trakymienė5, Alan Faraj6, Jakob Oemar Gjørret6, Kristoffer Winther Balling6, Thomas Porstmann7, Hermann Eichler8
MATERIALS AVAILABLE
Coming soon
18:30
ET
PO047
POSTER
Non-joint bleeds in patients with haemophilia A or B without inhibitors: Results from the concizumab phase 3 explorer8 study
Víctor Jiménez Yuste1, Ei Kinai2, Renée Brown Frandsen3, Fernanda Martinez Garcia3, Laura Villareal Martinez4, Lynn Malec5, Jerzy Windyga6
MATERIALS AVAILABLE
Coming soon
18:30
- 19:30
ET
PO054
POSTER
Patient experience with Mim8 prophylaxis: 52-week patient-reported outcomes in adolescents and adults with haemophilia A (FRONTIER2)
Cédric Hermans¹, Sanjay Ahuja², Hazza Alzahrani³, Cihan Ay⁴, Peter Kampmann⁵, Samya Obaji⁶, Sophie Susen⁷, Ciprian Ionut Tomuleasa⁸, Lize van Vulpen⁹, Amalie Rhode Høgh Nielsen¹⁰, Ilgiz Rakhmatullin¹⁰, Carmen Escuriola-Ettingshausen¹¹
MATERIALS AVAILABLE
Coming soon
18:30
- 19:30
ET
PO055
POSTER
Concizumab efficacy in Haemophilia A/B in an Intra-Patient Comparison vs Previous prophylaxis (Phase 3 Explorer8 study): Post-hoc Sensitivity Analysis
Hermann Eichler1, Anthony KC Chan2, Renée Brown Frandsen3, Fernanda Martinez Garcia3, Allison P Wheeler4, Pratima Chowdary5
MATERIALS AVAILABLE
Coming soon
18:30
- 19:30
ET
PO053
POSTER
Mim8 prophylaxis in children with haemophilia A: 52-week caregiver-reported outcomes from FRONTIER3
Karin Fijnvandraat,1 Rubén Berrueco,2 Matteo Luciani,3 Andrea Paramo Florencio,4 Jay Jay Thaung Zaw,4 Paula Kjöllerström5
MATERIALS AVAILABLE
Coming soon
18:30
- 19:30
ET
PO119
POSTER
Real-world efficacy and safety of concizumab in patients with haemophilia B with inhibitors from the early access program in France
Alexandre Butelet,1 Christine Biron-Andréani,2 Valérie Chamouard,3-4 Catherine Chatelanaz,5 Vincent Cussac,5 Roseline d’Oiron,6-7 Yesim Dargaud,3-4 Stéphanie Desage,4 Hélène Gatti,8 Antoine Rauch,9 Sophie Susen,9 Caroline Galeotti6
MATERIALS AVAILABLE
Coming soon
Friday, 06 February 2026
08:30
- 10:00
ET
OR09
ORAL PRESENTATION
Mim8 prophylaxis in children with haemophilia A: 52-week efficacy and safety outcomes from FRONTIER3
Gili Kenet,1 Manuel Carcao,2 Nita Radhakrishnan,3 Runhui Wu,4 Andrea Paramo Florencio,5 Jay Jay Thaung Zaw,5 Johnny Mahlangu6
MATERIALS AVAILABLE
Coming soon
Keywords